Press release: InMed Pharmaceuticals announces completed enrollment of their phase 1 trial of INM-755 CBN cream

We are pleased to announce that we have successfully included all healthy volunteers for InMed pharmaceuticals' phase 1 clinical trial with INM-755, a cannabinol cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. We look forward to working together with InMed on their second trial in the coming months!

Click here to read InMed's full press release.